🦴 #BoneHealth in newly diagnosed female #BreastCancer patients in China 🇨🇳 ❗ 63.2% have Abnormal Bone Mass 🔺 92.3% with Vitamin D deficiency ⚠️ 5.5x ⬆️ risk of ABM in BC 🆚 controls 🧑‍⚕️ Young BC patients (<45) 9x higher risk @oncoalert.bsky.social @nature.com 👉 nature.com/articles/s41598-024-84698-1

Urinary DNA methylation test: ✅89% sensitivity for high-grade or invasive #BladderCancer‼️ ✅Outperforms NMP22 & urine cytology tests with high specificity ✅Excellent negative predictive value 🔽Suboptimal positive predictive value @oncoalert.bsky.social jamanetwork.com/journals/jam...

💫 Phase 3 #KEYNOTE756 trial - 1⃣st interim analysis: 💫 ✅ Pembro + chemo ⬆️ pCR in high-risk early ER+/HER2− #BreastCancer (24.3% 🆚 15.6%) ⚠️ Manageable safety 📊 EFS data maturing 📰 Read more: nature.com/articles/s41... @oncoalert.bsky.social

Dear Colleagues, Don’t miss #OncoAlertColloquium & our #BreastCancer Faculty: brilliant dr Matteo Lambertini 🇮🇹, presenting on #FertilityPreservation (year in review) on February 5, 2025. REGISTER for FREE HERE 👉 buff.ly/3CChgre @oncoalert.bsky.social

This article explores the social, psychological & cognitive factors contributing to overtreatment at the #EOL and strategies to address them. @oncoalert.bsky.social www.esmoopen.com/article/S205...

Final OS analysis from #FALCON: ✅ No significant difference between fulvestrant (44.8 months) and anastrozole (42.7 months) in ET-naive HR+ #ABC ✅ 15% ⬇️ risk of death with fulvestrant in nonvisceral disease (65.2 vs. 47.8 months) @oncoalert.bsky.social ascopubs.org/doi/full/10.12…

🆕 data from KATHERINE trial confirms T-DM1 improves OS & sustains IDFS in HER2+ early #BreastCancer with residual disease after neoadjuvant therapy. 7-year IDFS: 80.8% (T-DM1) 🆚 67.1% (trastuzumab) 7-year OS: 89.1% (T-DM1) 🆚 84.4% (trastuzumab) @oncoalert.bsky.social nejm.org/doi/full/10.10…

On January 17, 2025🚨FDA approved☑️datopotamab deruxtecan-dlnk for unresectable/ metastatic, HR-positive, HER2-negative #BreastCancer 🎀who have received prior endocrine and chemotherapy for unresectable/metastatic disease. 🍀 #Oncology #FDAapproval @oncoalert.bsky.social www.fda.gov/drugs/resour...

Intratumoral💉#pembrolizumab & mRNA-2752 for high-risk #DCIS : Phase 1 nonrandomized trial ✅80% response rate ❌no major systemic toxicities ✅ complete tumor resolution in some➡️possible surgery reduction 🎀 ongoing studies needed @oncoalert.bsky.social @jama.com shorturl.at/W7pU2

Review of🔑clinical trials in #CRC in 2024 KRYSTAL-1: Adagrasib + cetuximab approved as 1⃣st KRAS G12C therapy for mCRC TransMet: survival benefits after liver transplant in liver-only mCRC NICHE-2: 95% major pathologic response with nivolumab + ipilimumab in dMMR colon cancer @oncoalert.bsky.social

Ultrasensitive ctDNA 🧬detection for pre-op stratification in early LUAD 🫁: Analysis from #TRACERx : buff.ly/4jl6fLR 🧬NeXT Personal detects #ctDNA in 81% pre-op LUAD 🫁, even in stage I. 🧬ctDNA <80 ppm predicts worse outcomes🆚ctDNA-negative cases. #LungCancer

🫀dysfunction, including heart failure, is a ⬆️concern for #BreastCancerSurvivors due to cardiotoxic therapy like anthracyclines & trastuzumab. A Korean study shows that ⬆️weight gain after a #BC diagnosis ⬆️ risk of heart failure💔 @oncoalert.bsky.social @jama.com ja.ma/42eruIO

Thrilled to share that after an incredible mentorship experience with Prof. Matteo Lambertini last year, I’ve been selected for the 2025 ESO mentorship program!🌟This year, I have the honor of being mentored by Prof. Bostjan Seruga. 🙌 Excited for the journey ahead! 😊😊😊 @oncoalert.bsky.social

🌟 #Supponc systematic review highlights the 🔼 use of #AI 🤖 in symptom prediction & monitoring for adult #CancerSurvivors. Pain, fatigue & nausea are🔑symptoms monitored with #AI tools like machine learning & NLP, revolutionizing patient care. 🌟 @oncoalert.bsky.social 👉 shorturl.at/vdKKQ

🌟Exploring neoadjuvant therapy for occult #BreastCancer with axillary presentation, a retrospective study of 114 patients suggests that targeted axillary surgery may be considered instead of axillary dissection in select cases. 🌟 Read more 👉 buff.ly/3Wfs9WI #Oncology #OncoAlertAF

Eribulin combined with trastuzumab & pertuzumab shows potential to become the🆕standard in 1️⃣st-line treatment for HER2+ locally advanced/metastatic #BreastCancer. Results from the phase III EMERALD trial suggest comparable efficacy to taxanes, with improved QoL. 👉 buff.ly/4hfnuMJ

Study of 542,778 women in the UK (16.6 yrs, 12,251 cases) links diet to #ColorectalCancer risk: 🔺 Higher risk: 🍷Alcohol &🥩 Red/processed meat 🔻 Protective: 🥛 Dairy (calcium) 🌾 Wholegrains & fiber 🍎 Fruits &🍳Cereal 🍋 Vitamin C &🥬Folate 🍚 Carbs Read more 👉 buff.ly/40eEVGd @oncoalert.bsky.social

🌟EMERALD: Eribulin + HP is an option for 1️⃣st-line treatment of locally advanced/metastatic HER2+ #BreastCancer : ✅ Noninferior efficacy to taxane ✅Toxicity differences: ⬇️ infusion reactions, diarrhea, and edema ⬆️ neutropenia @oncoalert.bsky.social @JCO_ASCO ascopubs.org/doi/10.1200/...

Dear colleagues, Join us for the 5th #OncoAlert Colloquium! 🚨🌟 👉 buff.ly/3CChgre 👈 📅 February 3-9, 2025 🎟️ FREE Registration 📰one week covering the latest in oncology Don’t miss this unique #oncology event! 🌍👩‍⚕️👨‍⚕️ @oncoalert.bsky.social #OncoAlertAF

✨AMBASSADOR✨: Adjuvant #Pembrolizumab🆚 Observation in Muscle-Invasive Urothelial Carcinoma 🕒FU: Median 44.8 months 📈DFS: 29.6 months (Pembro) 🆚 14.2 months (Obs) HR 0.73 (p=0.003) ⚠️AEs G≥3: 50.6% (Pembro) vs 31.6% (Obs) @oncoalert.bsky.social @nejm.org 👉 www.nejm.org/doi/full/10....

⏳Delayed nephrectomy in #mRCC pts with CR/mPR after #immunotherapy shows🍀promising outcomes (48% progression-free at 29.6 months) but comes with ⬆️ surgical complexity - 65.7% cases faced challenges when tumor downsizing >10%. 👉 link.springer.com/article/10.1... @oncoalert.bsky.social #OncoAlertAF

🚨The @oncoalert.bsky.social Video Journal 🚨 🌟This week, our #OncoAlertAF colleague @biagioricciutimd.bsky.social guides us through his paper in @jama.com:Deep Learning Model for Predicting Immunotherapy Response in Advanced Non–Small Cell Lung Cancer 🎥 Watch the highlights 👇

💡CMG901, the 1️⃣st #ADC targeting Claudin 18.2, demonstrated promising antitumor activity in a phase 1 trial in patients with advanced #gastric and #GEJ cancers: ⚠️Common AEs were vomiting, anorexia, proteinuria, anemia (Gr ≥3 in 68%) Read more: buff.ly/3PmhYfk

💡Great overview of the role of #immunotherapy in advanced #LUSC 🫁and the remaining questions: optimizing regimens, identifying robust biomarkers, and exploring emerging strategies like💉next-generation ICIs, bispecific antibodies and personalized vaccines. #Oncology

🌟Study of 257 Finnish #BreastCancer pts identified🔑predictive factors for response to neoadjuvant therapy. @springernature.bsky.social Key findings: ⚠️⬇️ PR = 3.8x⬆️mortality risk Personalized, risk-adapted surveillance & treatment is crucial! @oncoalert.bsky.social link.springer.com/article/10.1...

✨C9741 trial 12-year FU insights in @JCO_ASCO: Dose-dense chemo shows sustained benefit in N+ #BreastCancer 📈+23% DFS (HR 0.77) 📈+20% OS (HR 0.80) 🔬Low SET2,3 biomarker = biggest benefit in ER+ ❌Tumor burden, molecular subtype, menopausal status ≠ predictive @oncoalert.bsky.social rb.gy/gyi9jm

🆕study in Nature Cancer uncovers how circulating tumor cell (#CTC) plasticity drives therapy resistance in metastatic #breastcancer via the NRG1–HER3 axis. Dual blockade of 🎯 NRG1–HER3 & FGFR1 signaling offers a path to #PrecisionMedicine. Read more: buff.ly/3Pniny0

🎀January is #CervicalCancerAwarenessMonth🎀 💡 #Prevention saves lives: ✅ #HPV vaccine: Effective protection against the cause ✅ Regular screenings - early detection: PAPA test & HPV test ✅ Treatment of precancerous lesions @oncoalert.bsky.social #CervicalCancer #Oncology

🌟 CamRelief Trial: Camrelizumab + chemo 🆚 placebo + chemo in early/locally advanced #TNBC patients: ✅ pCR: 📈 56.8% with camrelizumab 🆚 44.7% with placebo (Δ +12.2%) 💡Neoadjuvant anti–PD-1 strategy shows promise!🍀 @oncoalert.bsky.social #oncology #Immunotherapy jamanetwork.com/journals/jam...

🆕Insights from the EUROPA trial🌟in @TheLancet : In women aged 70+ with low-risk, early #breastcancer, radiotherapy 🆚 endocrine therapy after BCS showed: 🎀Better HRQoL at 24 months (-3.4 vs -9.8, p=0.045) 🎀Fewer adverse events (67% vs 85%) @oncoalert.bsky.social thelancet.com/journals/lanon…

In an exploratory analysis of the #PALLAS trial, @elisaagostinetto.bsky.social et al. 💡explored impact of concomitant use palbociclib 💊with PPIs on survival outcomes 📊in #breastcancer . Read more in @ESMO_Open 👇🏻 sciencedirect.com/science/articl… @oncoalert.bsky.social #Oncologygy

Oncology leads the way! 🚀 🧬 In 2024, the FDA approved ✅50 new therapies, with 15 (30%) 🎯targeting cancer – including multiple first-in-class therapies and the 11th PD1/PDL1 inhibitor. @oncoalert.bsky.social #Oncology #FDAApprovals #Innovation nature.com/articles/d4157…

🆕 #HELEN006 trial: weekly nab-paclitaxel with trastuzumab & pertuzumab showed a higher pCR (66.3%) 🆚 docetaxel + carboplatin (57.6%) in HER2-positive #eBC, with fewer severe side effects. A potential new standard for neoadjuvant therapy❓ @oncoalert.bsky.social thelancet.com/journals/lanon…

💫Exciting results from the MECCA Phase III trial: Metronomic capecitabine combined with an aromatase inhibitor significantly improved ✅ PFS and OS in patients with HR+/HER2-negative metastatic breast cancer. A promising first-line therapy!💫 🖇️ ascopubs.org/doi/10.1200/JC… @oncoalert.bsky.social

🆕 trial in @JournalCancer explores the feasibility of a screening program using MCED tests and whole-body MRI in high-risk populations. ✅ The findings highlight the potential for earlier detection across multiple cancer types, possibly improving outcomes. 💫 #OncoAlertAF #CancerScreening #Oncology

Super application ✨ With #OncoBlast learning is fun! Free CME, short courses, knowledge renewal are the reasons why I liked #OncoBlast @binaytara.bsky.social #oncsky #medsky #meded #academicsky

💫Great discusssions during #SABCS24 on CDK4/6inh and ADC therapy for HER2+ #BreastCancer (FASCINATE & PATINA) created in collaboration @oncoalert.bsky.social & high5md More discussions coming soon... 💫

Happy New Year 🎄 ✨✨✨✨✨✨✨✨✨✨✨✨

On December 27, 2024, @fda.gov approved ✅ #Subcutaneous nivolumab 💉across approved adult, solid tumor indications, ❌ except in combination with intravenous ipilimumab www.fda.gov/drugs/resour... ✨✨✨✨✨✨✨✨✨✨✨✨✨ @oncoalert.bsky.social

Wrapping up another fantastic #SABCS! Amazing, practice-changing data were presented. I’ve updated the algorithms and added key studies from the meeting— I finally ran out of space in HR+ disease! #SABCS24 @oncoalert.bsky.social

What happiness and motivation this morning! 🤩🤩🤩 I’ve been selected to participate in Open Medical Institut - #OMI seminar on Breast and Gynecologic Cancers which has been my long-time dream! 🫶🫶🫶

While waiting for the very much awaited presentation at #SABCS24, results of EMBER-3 are out in @NEJM‼️ Imlunestrant–abemaciclib significantly ⬆️ PFS as compared with imlunestrant, regardless of ESR1-mutation status @oncoalert.bsky.social www.nejm.org/doi/full/10....

General session 1️⃣ at #SABCS24 starts with the very much awaited results of EMBER-3 3 co-primary endpoints: 1️⃣In ESR1-mut pts, imlunestrant ⬆️ PFS vs. ET SoC 2️⃣No significant difference in all pts 3️⃣Imlu + abema ⬆️ PFS (vs. Imlu) in all pts, regardless of ESR1-mut @oncoalert.bsky.social

At #SABCS24 LBA session - @dradityabardia on Efficacy and Safety of T-DXd by Pace of Disease Progression on Prior Endocrine-Based Therapy in DESTINY-Breast06 T-DXd ⬆️PFS regardless of time to progression on 1st line CDK4/6i+ET or type of endocrine resistance @oncoalert.bsky.social

Great presentation on the Association Between Risk-Reducing Surgeries and Survival in Young BRCA Carriers with Breast Cancer by Matteo Lambertini at #SABCS24 Data from >5000 patients show risk-reducing mastectomy and RRSO both improve OS, DFS, and BCFI @oncoalert.bsky.social

10 year follow up on OlympiA shows persistent benefit in iDFS, OS. #SABCS24 @oncoalert.bsky.social

The OncoAlert🚨 #SABCS24 DAY1 Round Up REGISTER AT www.OncoAlert360.com OR buff.ly/48Xpgz0 ✅meta-analysis examining the long-term outcomes of either omitting immediate surgery ✅PADMA: ✅DESTINY-Breast06 ✅SOLTI VALENTINE: ✅KEYNOTE-522 youtu.be/31ak3efSNGs

🔝🔝🔝 experts in oncology 🤩

👀 The @ptarantinomd.bsky.social 🔝 abstract list for #SABCS24! 🎀#bcsm 🔜🔜🔜 @oncoalert.bsky.social